Welcome

By clicking "Continue to the HCP site," you are certifying that you are a licensed US healthcare professional (HCP) and a US resident.

If you are a patient who wants to learn more about VASCEPA, click vascepa.com

For adults on maximally tolerated statins with TG ≥150 mg/dL and established CVD or diabetes and ≥2 CVD risk factors

Unprecedented CV risk reduction on top of a statin1

Myth: Reduction in LDL-C eliminates Persistent CV Risk (P-CVR).

Fact: Dr. Payal Kohli, an expert in preventive cardiology, says P-CVR remains despite LDL-C control.2-4

Watch Dr. Kohli review the LDL-C facts and myths below

Learn more about the Important Safety Information
See the groundbreaking results from the VASCEPA CV Outcomes Trial (REDUCE-IT®)View now

Approximately every 37-40 seconds, someone will experience an MI or Stroke, or die from CVD in the United States. And the prevalence of heart disease in both men and women is only expected to grow.5,6 But, who is at risk?

Meet the patient types who may benefit from VASCEPA

Maria's photo

Not an actual VASCEPA patient.

Maria, 57

  • Established CVD and history of MI
  • On statin therapy
  • TG: 185 mg/dL

Reason for visit: Had a prior MI and is coming in for her 3-month, post-MI visit

Clinical CVD diagnosis:

  • MI with stent placement 3 months ago
  • Hypertension
  • High cholesterol

Family history:

  • CVD, father died from an MI at 63 yrs. old

Medications:

  • Atorvastatin 80 mg QD
  • Valsartan 160 mg QD
  • Clopidogrel 75 mg QD
  • Metoprolol ER 100 mg QD
  • ASA 325 mg QD

Diagnostics:

  • LDL-C: 68 mg/dL
  • TG: 185 mg/dL
  • HDL-C: 40 mg/dL
  • BP: 132/80 mm Hg
  • BMI: 34

VASCEPA can help patients like Maria

See how
Robert's photo

Not an actual VASCEPA patient.

Robert, 65

  • Established CVD and history of stroke
  • On statin therapy
  • TG: 260 mg/dL

Reason for visit: Had a prior stroke and is coming in for his routine office visit

Clinical CVD diagnosis:

  • Stroke at 64 yrs. old
  • High cholesterol
  • PAD
  • Hypertension

Family history:

  • Extensive family history of CV disease

Medications:

  • Rosuvastatin 20 mg QD
  • Clopidogrel 75 mg QD
  • ASA 325 mg QD
  • Valsartan 160 mg QD
  • Amlodipine 10 mg QD

Diagnostics:

  • LDL-C: 88 mg/dL
  • TG: 260 mg/dL
  • HDL-C: 40 mg/dL
  • BP: 132/80 mm Hg
  • BMI: 25

VASCEPA can help patients like Robert

See how

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

IMPORTANT SAFETY INFORMATION

• VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

• VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

• It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur

INDICATIONS AND LIMITATIONS OF USE

• VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

• VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

• VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin

• Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)

• Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)

• Adverse Events, Product Complaints, or Special Situations may be reported by contacting AmarinConnect at 1-855-VASCEPA, emailing [email protected], or calling the FDA at 1-800-FDA-1088

• Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see full Prescribing Information for more information on VASCEPA.

Visual representations are for illustrative purposes only. The capsule shown is not an identical representation of the product.

ASA=acetylsalicylic acid; BMI=body mass index; BP=blood pressure; CV=cardiovascular; CVD=cardiovascular disease; ER=extended release; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; MI=myocardial infarction; PAD=peripheral arterial disease; QD=once daily.

References: 1. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2021. 2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. 3. Bhatt DL, Steg PG, Miller M, et al; for the REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. 4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397. 5. Virani SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596. 6. American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035. https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf. Accessed October 22, 2020.

CO and VT prescribers only: Click here for statutory price disclosure information.

VASCEPA, Amarin, REDUCE-IT, and Vascepa/Amarin logos are registered trademarks of Amarin Pharmaceuticals Ireland Limited.

All other trademarks are the property of their respective companies.

© 2023 Amarin Pharmaceuticals Ireland Limited.  All rights reserved.  VAS-03038v14  02/23

This website, Vascepa.com, Vascepasavings.com, Truetoyourheart.com, and the corporation's website, amarincorp.com, are the only company-sanctioned websites pertaining to the Amarin group of companies or its product, Vascepa® (icosapent ethyl) capsules. The Amarin group of companies is not responsible for false or misleading materials contained on other non–Amarin-controlled websites or other social media sites.